- Home
- / Axsome Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Axsome Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$90.3
2024-10-29
Market Capitalization
$4.3 B
2024-10-29
Revenue
$638.5 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 270.6M | 385.7M | 638.5M | |||||||
| Cost of goods sold | 5.2M | |||||||||
| General and administrative expense | 6.3M | 7.2M | 9.4M | 13.6M | 28.9M | 66.6M | 159.3M | 323.1M | 411.4M | 570.6M |
| Operating expense total | 27.5M | 27.2M | 32.8M | 67.2M | 99.1M | 174.6M | 521.4M | 891.8M | 753.9M | |
| Depreciation and amortization | 4.1M | 6.4M | ||||||||
| EBIT | (27.5M) | (27.2M) | (32.8M) | (67.2M) | (99.1M) | (124.7M) | (179.8M) | (231.8M) | (280.6M) | (166.8M) |
| EBIT margin, % | -85.7% | -72.7% | -26.1% | |||||||
| Investment income | (132.4K) | (1.3M) | (1.1M) | (1.2M) | (2.6M) | (5.7M) | (7.3M) | (6.5M) | (6.6M) | (6.6M) |
| Interest income | 15.0M | 9.4M | ||||||||
| Interest expense | 16.7M | 21.6M | ||||||||
| Pre tax profit | (238.3M) | (287.1M) | (183.7M) | |||||||
| Income tax expense | 960.0K | 85.0K | (530.0K) | |||||||
| Net Income | (27.2M) | (28.9M) | (31.0M) | (68.3M) | (102.9M) | (130.4M) | (187.1M) | (239.2M) | (287.2M) | (183.2M) |
| EPS | (4.6) | (5.3) | (6.0) | (3.7) |